on April 4, 2005
Published online before print April 4, 2005, doi: 10.1161/01.HYP.0000161880.59963.da
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 27, 2005
From the Blood Pressure Unit, Department of Cardiac and Vascular Sciences, St. George’s Hospital Medical School, London, UK. * To whom correspondence should be addressed. E-mail: gmacgreg{at}sghms.ac.uk.
Abstract--Some evidence suggests that long-term angiotensin-converting enzyme (ACE) inhibition may become less effective, thereby increasing angiotensin II levels, which could be inhibited by the addition of an angiotensin receptor blocker. We conducted a meta-analysis of randomized trials with searches of MEDLINE, EMBASE, and Cochrane databases. Overall, the combination of an ACE inhibitor and an angiotensin receptor blocker reduced ambulatory blood pressure by 4.7/3.0 mm Hg (95% confidence interval [CI], 2.9 to 6.5/1.6 to 4.3) compared with ACE inhibitor monotherapy and 3.8/2.9 mm Hg (2.4 to 5.3/0.4 to 5.4) compared with angiotensin receptor blocker monotherapy. Clinic blood pressure was reduced by 3.8/2.7 mm Hg (0.9 to 6.7/0.8 to 4.6) and 3.7/2.3 mm Hg (0.4 to 6.9/0.2 to 4.4) compared with ACE inhibitor and angiotensin receptor blocker, respectively. However, the majority of these studies used submaximal doses or once-daily dosing of shorter-acting ACE inhibitors and, when a larger dose of shorter-acting ACE inhibitor was given or a longer-acting ACE inhibitor was used, there was generally no additive effect of the angiotensin receptor blocker on blood pressure. Proteinuria was reduced by the combination compared with ACE inhibitor and angiotensin receptor blocker monotherapy, an effect that was independent of blood pressure in several studies, suggesting that the combination could have benefits in proteinuric nephropathies. None of the studies was of sufficient size and duration to determine whether there may be safety concerns. In conclusion, although there is a small additive effect on blood pressure with an ACE inhibitor-angiotensin receptor blocker combination, the routine use of this combination in uncomplicated hypertension is not recommended until more carefully controlled studies are performed.
Revised on January 27, 2005
Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension
Timothy W.R. Doulton;
Key words: angiotensin-converting enzyme • hypertension • meta-analysis • proteinuria • receptors, angiotensin • renin-angiotensin system
This article has been cited by other articles:
 |
|
 |
|
  R. Haynes, P. Mason, K. Rahimi, and M. J. Landray Dual blockade of the renin-angiotensin system: are two better than one? Nephrol. Dial. Transplant., December 1, 2009; 24(12): 3602 - 3607. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bohm, F. Mahfoud, C. Werner, K. Teo, and M. Baumhakel Cardiovascular protection: a breakthrough for high-risk patients Eur. Heart J. Suppl., December 1, 2009; 11(suppl_F): F19 - F26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Jessup, B. M. Westwood, M. C. Chappell, and L. Groban Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 245 - 257. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Berl Review: Renal protection by inhibition of the renin-angiotensin-aldosterone system Journal of Renin-Angiotensin-Aldosterone System, March 1, 2009; 10(1): 1 - 8. [Abstract] [PDF]
|
|
|
|
 |
|
 F. H. Messerli The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J. Am. Coll. Cardiol., February 10, 2009; 53(6): 468 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. de Resende, S. L. Amaral, C. Moreno, and A. S. Greene Congenic strains reveal the effect of the renin gene on skeletal muscle angiogenesis induced by electrical stimulation Physiol Genomics, October 8, 2008; 33(1): 33 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schindler ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 233 - 248. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Mrkobrada, H. Thiessen-Philbrook, R. B. Haynes, A. V. Iansavichus, F. Rehman, and A. X. Garg Need for Quality Improvement in Renal Systematic Reviews Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1102 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Chapman Approaches to Testing New Treatments in Autosomal Dominant Polycystic Kidney Disease: Insights from the CRISP and HALT-PKD Studies Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1197 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Linas Are Two Better Than One? Angiotensin-Converting Enzyme Inhibitors Plus Angiotensin Receptor Blockers for Reducing Blood Pressure and Proteinuria in Kidney Disease Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(Supplement_1): S17 - S23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. M. Saweirs and J. Goddard What are the best treatments for early chronic kidney disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix31 - ix38. [Full Text] [PDF]
|
|
|
|
 |
|
 W. B.A. Eijkelkamp, Z. Zhang, G. Remuzzi, H.-H. Parving, M. E. Cooper, W. F. Keane, S. Shahinfar, G. W. Gleim, M. R. Weir, B. M. Brenner, et al. Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1540 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Khosla and G. Bakris Lessons Learned from Recent Hypertension Trials about Kidney Disease Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 229 - 235. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Stults and R. E. Jones Management of Hypertension in Diabetes Diabetes Spectr, January 1, 2006; 19(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Donnelly Review: Managing cardiovascular risk in patients with diabetes The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 325 - 329. [Abstract] [PDF]
|
|
|
|
 |
|
 F. A Snyder Drug combinations and all cause mortality in heart disease: Dosages and types of ACE inhibitors need to be known BMJ, July 16, 2005; 331(7509): 159 - 159. [Full Text]
|
|